NewsRoom Articles - Page 40 of 247

TuesdayJul 22, 2025 10:00 am

Unexpected Finding Potentially Opens the Door to Universal Vaccines Against Cancer

A team of researchers testing an experimental messenger RNA (mRNA) vaccine managed to ramp up the ability of immunotherapy to combat tumors in a study using mouse models. This finding potentially brings scientists one step closer to developing universal vaccines that can supercharge the immune system in its fight against cancer. The team, based at University of Florida, found that using the test vaccine together with immune checkpoint inhibitors had the effect of strengthening the immune system’s ability to reduce or even eliminate tumors in the mice. What the researchers found surprising was that the anticancer effect was triggered even…

FridayJul 18, 2025 10:00 am

Individuals Who Develop Multiple Sclerosis Have More Doctor Visits Decades Before Their Diagnosis

A new study has found that individuals who are later diagnosed with multiple sclerosis (MS) tend to visit their doctor more, are admitted to hospitals more, and visit emergency rooms more frequently decades before they are eventually diagnosed with MS in comparison to those who don’t develop the condition. This often happens more than 20 years before an MS diagnosis is made. These findings were made by researchers in Canada who used healthcare data from Ontario, the country’s province with the largest population. The study was funded by MS Canada and the National MS Society. The team conducted a retrospective…

FridayJul 18, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma. “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states. No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks. Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and…

ThursdayJul 17, 2025 10:00 am

Study Provides Valuable Insights About Non-Smokers Who Develop Lung Cancer

Lung cancer, one of the most common types of cancer, has for a long time been known to largely develop among smokers. However, recent studies have established that around one quarter of people diagnosed with lung cancer has never smoked. This has baffled the scientific community as there was no clear explanation why such a significant proportion of lung cancer patients didn’t have a history of smoking. A study has now provided key insights into the factors that could predispose many non-smokers to the development of lung cancer. This study was published in the journal Nature early this month. The…

TuesdayJul 15, 2025 10:00 am

KFF Poll Reveals the Challenges Americans Face in Meeting Their Healthcare Costs

Recent polling by KFF has provided insights into the numerous challenges that Americans face in meeting their health care costs. The poll, conducted in May and whose findings were published in June this year, shows that one of the major worries that American families face is having unexpected medical bills to pay. From the poll, the research team found that nearly half of all adults in the U.S. find it difficult to afford their health care costs. 1-in-4 of those polled also revealed that they or a member of their household had experienced problems in meeting their health care costs…

FridayJul 11, 2025 10:00 am

Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases

Spotlight Diagnostics, a startup based in Eindhoven, Netherlands, is developing a test kit that will enable personnel to rapidly test for infectious diseases without requiring lab facilities. The kit targets infectious diseases like malaria, Chlamydia, gonorrhea and others that take a huge toll on human life. For example, malaria claims at least 600,000 lives globally each year, with most of these fatalities happening in low-income countries. Sub-Saharan Africa accounts for approximately 95% of this annual toll. The new test is intended to facilitate rapid diagnostics outside a lab in resource-constrained settings. In low-income countries, healthcare workers often administer treatment without…

ThursdayJul 10, 2025 9:00 am

New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer

A new study that has been published in JAMA Network has found that military veterans that sustained traumatic brain injuries (TBIs) had an elevated risk of developing cancerous brain tumors. Doctor Ian Stewart, who led this breakthrough study, explains that his team found that veterans that sustained moderate or severe TBIs had their likelihood of developing brain cancer increase by 90%. Glioblastoma, or GBM, is the most common type of brain cancer, and fatalities from this cancer are high. On average, individuals diagnosed with this type of cancer survive for 14 months only. While this link between TBIs and GBM…

TuesdayJul 08, 2025 10:00 am

Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice

University of Sydney researchers have, for the first time ever, targeted a malfunctioning protein in mice having symptoms akin to Parkinson’s symptoms and successfully improved motor function in the mice. This breakthrough finding could open the door to finding a similar way to treat Parkinson’s disease in humans. For more than 10 years, the team worked to establish the biological mechanisms which underpin Parkinson’s. Their interest was in uncovering new ways to slow the progression of the disease or even treat it. In 2017, they published research documenting SOD1 protein abnormalities within the brain and showed that these abnormalities were…

TuesdayJul 08, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA. Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression. HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49%…

MondayJul 07, 2025 11:50 am

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

The FDA offered supportive feedback on Clene’s proposed statistical analysis plan during a recent Type C meeting. The neurofilament biomarker analysis results could support an accelerated approval submission for CNM-Au8 later in 2025. Clene has two additional FDA meetings scheduled in Q3 2025 to discuss ALS survival data and its MS program. Nearly 200 ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8. The analysis aims to validate the neuroprotective effects shown in previous HEALEY Platform Trial results. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial…